Aesculap Biologics

Contact:
Email:
Phone:
(610) 791-6880
Social:
Gold Booth Template

About NOVOCART 3D®

Aesculap Biologics, LLC is currently conducting a Phase 3 clinical trial to bring NOVOCART® 3D to the United States from Europe where it originated and has been implanted in more than 9000 patients since 2003. NOVOCART 3D is an investigational biologic-device combination product consisting of an autologous chondrocyte implant derived from the patient’s own cartilage cells to regenerate articular cartilage in defects of the knee. The procedure involves an arthroscopic procedure to obtain a cartilage biopsy from a non-weight bearing location in the knee joint. The tissue is sent to the Aesculap Biologics manufacturing facility where the cartilage cells (chondrocytes) are isolated and grown in culture. Approximately three weeks later, the cells are added onto a collagen device and sent to the physician to be implanted into the defect. NOVOCART 3D is not approved for use in the United States or in Canada outside of the study.  For more information, visit www.aesculapbiologics.com.

About Aesculap Biologics, LLC

Aesculap Biologics is a regenerative medicine company focused on biological approaches to the repair and regeneration of diseased or damaged tissues. Using a combination of cells, growth factors and smart biomaterial devices, Aesculap Biologics products are intended to stimulate and support the synthesis of new tissue and enhance the body’s own regenerative power. Aesculap Biologics, a B. Braun company, is part of a 180-year-old global organization focused on meeting the needs of an ever-changing healthcare community.

Marketing & Product Content

NOVOCART 3D®

Booth Content

About NOVOCART 3D® Aesculap Biologics, LLC is currently conducting a Phase 3 clinical trial to bring NOVOCART® 3D to the United States from.. →

Additional Company Representatives

Sarah Collins
Director of Clinical Studies
Aesculap Biologics
Cell: (310)948-8400
Email: Sarah.collins@aesculapbiologics.com

Search/Sort
Post Subtypes
Topics
NOVOCART 3D® NOVOCART 3D®

About NOVOCART 3D® Aesculap Biologics, LLC is currently conducting a Phase 3 clinical trial to bring NOVOCART® 3D to the United States ...

Booth Content
Booth Content
0 Booth-Content-Booth-Content jplist-topic-bronze-sponsor jplist-topic-NOVOCART-3D-- jplist-topic-Aesculap 0 379814 379814 About NOVOCART 3D® Aesculap Biologics, LLC is currently conducting a Phase 3 clinical trial to bring NOVOCART® 3D to the United States from Europe where it originated and has been implanted in more than 9000 patients since 2003. NOVOCART 3D is an investigational biologic-device combination product consisting of an autologous chondrocyte implant derived from the patient’s own cartilage cells to regenerate articular cartilage in defects of the knee. The procedure involves an arthroscopic procedure to obtain a cartilage biopsy from a non-weight bearing location in the knee joint. The tissue is sent to the Aesculap Biologics manufacturing facility where the cartilage cells (chondrocytes) are isolated and grown in culture. Approximately three weeks later, the cells are added onto a collagen device and sent to the physician to be implanted into the defect. NOVOCART 3D is not approved for use in the United States or in Canada outside of the study.  For more information, visit www.aesculapbiologics.com.

NOVOCART 3D®

Booth Content

About NOVOCART 3D® Aesculap Biologics, LLC is currently conducting a Phase 3 clinical trial to bring NOVOCART® 3D to the United States from Europe ...

No results found